Johnson & Jhonson’s
Apr 06, 2021
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application
Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics has announced a deal with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 to prevent and treat...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
